Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Lycia Therapeutics has raised $75.0M in total funding. The most recent round was Series D. The last funding was announced in June 2026.
Lycia Therapeutics's investors include Franklin Templeton, Eli Lilly, Janus Henderson Investors, Redmile Group, Balyasny Asset Management.
Lycia Therapeutics is headquartered in South San Francisco, United States.
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Lycia Therapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lycia Therapeutics — Funding & Investors." VCBacked, June 25, 2026, https://www.vcbacked.co/company/lycia-therapeutics. Accessed September 13, 2026.
VCBacked. (2026). Lycia Therapeutics — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/lycia-therapeutics
{{cite web |title=Lycia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lycia-therapeutics |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated